Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Multiple Myeloma × Capsules × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lung Neoplasms 1 Lower Urinary Tract Symptoms 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Adenocarcinoma of Lung 1

Interventions

Dexamethasone 295 Bortezomib 160 Lenalidomide 155 Cyclophosphamide 143 Melphalan 107 Calcium Dobesilate 94 daratumumab 83 carfilzomib 59 pomalidomide 58 fludarabine phosphate 53 Peripheral Blood Stem Cell Transplantation 53 Thalidomide 46 Filgrastim 46 Mycophenolic Acid 42 Busulfan 42 ixazomib 40 fludarabine 36 Granulocyte Colony-Stimulating Factor 35 Whole-Body Irradiation 34 Tacrolimus 34 dexamethasone acetate 29 Etoposide 28 Cyclosporine 28 Antilymphocyte Serum 27 isatuximab 25 dexamethasone 21-phosphate 24 auricularum 23 plerixafor 21 Radiotherapy 21 elotuzumab 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡